Artificial intelligence's usage in pharmaceutical technology has grown over time, and it may save time and money while offering a greater knowledge of the interactions between different formulations and process factors. Artificial intelligence is an area of computer science concerned with problem solving through the use of symbolic programming. Artificial intelligence (AI) employs personalized knowledge and learns from the solutions it generates to handle both particular and complex issues. Remarkable developments in processing power, along with advances in AI technology, have the potential to transform the drug development process. The pharmaceutical sector is now facing difficulty in continuing drug development programs due to higher R&D expenses and decreased efficiency. Artificial Neural Network (ANN) technologies are being developed for predicting relationships in data.Machine learning and deep learning are also being used to examine various machine parameters and regulate them accordingly to get the desired results.Thus, Artificial Intelligence programs serve as effective solutions for creating a medicinal product. They are also utilized in clinical studies to generate and evaluate data collected from patient information. As a result, in this article, we will discuss several applications of artificial intelligence in pharmaceutical product development, providing a clear picture of how AI has an efficient influence on the pharmaceutical industry

1.      Krishnaveni Ch, Arvapalli S, Sharma JVC. Artificial Intelligence In Pharma Industry-A Review. International Journal of Innovative Pharmaceutical Sciences and Research 2019;7:37–50. https://doi.org/10.21276/IJIPSR.2019.07.10.506.

2.      Duch W, Swaminathan K, Meller J. Artificial Intelligence Approaches for Rational Drug Design and Discovery. Current Pharmaceutical Design 2007;13:1497–508. https://doi.org/10.2174/138161207780765954.

3.      Borisa P, Singh D, Rathore KS. Impact of Artificial Intelligence on Pharma Industry. Manipal Journal of Pharmaceutical Sciences 2020;6:54–9.

4.      Agatonovic-Kustrin S, Beresford R. Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research. Journal of Pharmaceutical and Biomedical Analysis 2000;22:717–27. https://doi.org/10.1016/s0731-7085(99)00272-1.

5.      Jiang F, Jiang Y, Zhi H, Dong Y, Li H, Ma S, et al. Artificial intelligence in healthcare: past, present and future. Stroke and Vascular Neurology 2017;2:230–43. https://doi.org/10.1136/svn-2017-000101.

6.      Leite ML, de Loiola Costa LS, Cunha VA, Kreniski V, de Oliveira Braga Filho M, da Cunha NB, et al. Artificial intelligence and the future of life sciences. Drug Discovery Today 2021;26:2515–26. https://doi.org/10.1016/j.drudis.2021.07.002.

7.      Kaul V, Enslin S, Gross SA. History of artificial intelligence in medicine. Gastrointestinal Endoscopy 2020;92:807–12. https://doi.org/10.1016/j.gie.2020.06.040.

8.      Amisha, Malik P, Pathania M, et al. Overview of artificial intelligence in medicine. J Family Med Prim Care 2019;8:2328-2331.

9.      Kalyane D, Sanap G, Paul D, Shenoy S, Anup N, Polaka S, et al. Artificial intelligence in the pharmaceutical sector: current scene and future prospect. The Future of Pharmaceutical Product Development and Research 2020:73–107. https://doi.org/10.1016/b978-0-12-814455-8.00003-7.

10.   Beneke F, Mackenrodt M-O. Artificial Intelligence and Collusion. IIC - International Review of Intellectual Property and Competition Law 2018;50:109–34. https://doi.org/10.1007/s40319-018-00773-x.

11.   Da Silva, I.N., Spatti, D.H., Flauzino, R.A., Liboni, L.H.B., Dos Reis Alves, S.F. Artificial Neural Networks. Springer International Publishing, 2017; 39.

12.   Vyas, M., Thakur, S., Riyaz, B., Bansal, K.K., Tomar, B., Mishra, V. Artificial intelligence: the beginning of a new era in pharmacy profession. Asian J. Pharm. 2018. 12, 72.

13.   Mak K-K, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today 2019;24:773–80. https://doi.org/10.1016/j.drudis.2018.11.014.

14.   Segler MHS, Kogej T, Tyrchan C, Waller MP. Generating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks. ACS Central Science 2017;4:120–31. https://doi.org/10.1021/acscentsci.7b00512.

15.   Seddon G, Lounnas V, McGuire R, van den Bergh T, Bywater RP, Oliveira L, et al. Drug design for ever, from hype to hope. Journal of Computer-Aided Molecular Design 2012;26:137–50. https://doi.org/10.1007/s10822-011-9519-9.

16.   Wang Q, Feng Y, Huang J, Wang T, Cheng G. A novel framework for the identification of drug target proteins: Combining stacked auto-encoders with a biased support vector machine. PLOS ONE 2017;12:e0176486. https://doi.org/10.1371/journal.pone.0176486.

17.   Bakkar N, Kovalik T, Lorenzini I, Spangler S, Lacoste A, Sponaugle K, et al. Artificial intelligence in neurodegenerative disease research: use of IBM Watson to identify additional RNA-binding proteins altered in amyotrophic lateral sclerosis. Acta Neuropathologica2017;135:227–47. https://doi.org/10.1007/s00401-017-1785-8.

18.   Okafo G. Adapting drug discovery to artificial intelligence. Drug Target Rev. 2018;5(2):50-2.

19.   Gayvert KM, Madhukar NS, Elemento O. A Data-Driven Approach to Predicting Successes and Failures of Clinical Trials. Cell Chemical Biology 2016;23:1294–301. https://doi.org/10.1016/j.chembiol.2016.07.023.

20.   Bain EE, Shafner L, Walling DP, Othman AA, Chuang-Stein C, Hinkle J, et al. Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia. JMIR mHealth and uHealth 2017;5:e18. https://doi.org/10.2196/mhealth.7030.

21.   Deliberato RO, Celi LA, Stone DJ. Clinical Note Creation, Binning, and Artificial Intelligence. JMIR Medical Informatics 2017;5:e24. https://doi.org/10.2196/medinform.7627.

22.   Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, Zhavoronkov A. Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data. Molecular Pharmaceutics 2016;13:2524–30. https://doi.org/10.1021/acs.molpharmaceut.6b00248.

23.   Kadurin A, Nikolenko S, Khrabrov K, Aliper A, Zhavoronkov A. druGAN: An Advanced Generative Adversarial Autoencoder Model for de Novo Generation of New Molecules with Desired Molecular Properties in Silico. Molecular Pharmaceutics 2017;14:3098–104. https://doi.org/10.1021/acs.molpharmaceut.7b00346.

24.   Ryu JY, Kim HU, Lee SY. Deep learning improves prediction of drug–drug and drug–food interactions. Proceedings of the national academy of sciences. 2018 May 1;115(18):E4304-11.

25.   Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics 2023;15:1916. https://doi.org/10.3390/pharmaceutics15071916.

26.   Chen M, Decary M. Artificial intelligence in healthcare: An essential guide for health leaders. Healthcare Management Forum 2019;33:10–8. https://doi.org/10.1177/0840470419873123.

27.   Magill E, Demartis S, Gavini E, Permana AD, Thakur RRS, Adrianto MF, et al. Solid implantable devices for sustained drug delivery. Advanced Drug Delivery Reviews 2023;199:114950. https://doi.org/10.1016/j.addr.2023.114950.